Does the media refer more to VKTX or TBPH?

In the previous week, Viking Therapeutics had 5 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for Viking Therapeutics and 3 mentions for Theravance Biopharma. Viking Therapeutics' average media sentiment score of 0.46 beat Theravance Biopharma's score of -0.05 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, TLX or TBPH?

Theravance Biopharma has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.31 -$7.12M N/A N/A Theravance Biopharma $107.46M 8.14 $105.89M $2.20 7.71

Does the media favor TLX or TBPH?

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 3 mentions for Theravance Biopharma. Telix Pharmaceuticals' average media sentiment score of 0.33 beat Theravance Biopharma's score of -0.05 indicating that Telix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TBPH or ARQT?

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 3 mentions for Theravance Biopharma. Arcutis Biotherapeutics' average media sentiment score of 0.25 beat Theravance Biopharma's score of -0.05 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BEAM or TBPH?

In the previous week, Beam Therapeutics had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Theravance Biopharma. Beam Therapeutics' average media sentiment score of 0.81 beat Theravance Biopharma's score of -0.05 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GPCR or TBPH?

In the previous week, Theravance Biopharma had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.05 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Theravance Biopharma (TBPH) Competitors

$16.97 +0.41 (+2.48%)

As of 06/23/2026 04:00 PM Eastern

Compare

TBPH vs. VKTX, TLX, ARQT, BEAM, and GPCR

Should you buy Theravance Biopharma stock or one of its competitors? MarketBeat compares Theravance Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Theravance Biopharma include Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), Arcutis Biotherapeutics (ARQT), Beam Therapeutics (BEAM), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Theravance Biopharma compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

In the previous week, Viking Therapeutics had 5 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for Viking Therapeutics and 3 mentions for Theravance Biopharma. Viking Therapeutics' average media sentiment score of 0.46 beat Theravance Biopharma's score of -0.05 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Theravance Biopharma has a net margin of 104.34% compared to Viking Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Theravance Biopharma	104.34%	18.84%	10.94%

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Viking Therapeutics currently has a consensus target price of $93.60, suggesting a potential upside of 168.89%. Theravance Biopharma has a consensus target price of $21.40, suggesting a potential upside of 26.10%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Theravance Biopharma has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Theravance Biopharma	$107.46M	8.14	$105.89M	$2.20	7.71

Viking Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Summary

Theravance Biopharma beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 3 mentions for Theravance Biopharma. Telix Pharmaceuticals' average media sentiment score of 0.33 beat Theravance Biopharma's score of -0.05 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Theravance Biopharma has a net margin of 104.34% compared to Telix Pharmaceuticals' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Theravance Biopharma	104.34%	18.84%	10.94%

Theravance Biopharma has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.31	-$7.12M	N/A	N/A
Theravance Biopharma	$107.46M	8.14	$105.89M	$2.20	7.71

Telix Pharmaceuticals presently has a consensus target price of $21.13, indicating a potential upside of 106.90%. Theravance Biopharma has a consensus target price of $21.40, indicating a potential upside of 26.10%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Telix Pharmaceuticals is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

99.1% of Theravance Biopharma shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Telix Pharmaceuticals has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

Summary

Theravance Biopharma beats Telix Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Theravance Biopharma (NASDAQ:TBPH) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

99.1% of Theravance Biopharma shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Theravance Biopharma has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.14	$105.89M	$2.20	7.71
Arcutis Biotherapeutics	$376.07M	8.74	-$16.14M	-$0.03	N/A

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 3 mentions for Theravance Biopharma. Arcutis Biotherapeutics' average media sentiment score of 0.25 beat Theravance Biopharma's score of -0.05 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Theravance Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

Theravance Biopharma has a net margin of 104.34% compared to Arcutis Biotherapeutics' net margin of -0.57%. Theravance Biopharma's return on equity of 18.84% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Theravance Biopharma presently has a consensus target price of $21.40, suggesting a potential upside of 26.10%. Arcutis Biotherapeutics has a consensus target price of $34.00, suggesting a potential upside of 29.43%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Arcutis Biotherapeutics beats Theravance Biopharma on 9 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Theravance Biopharma has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	24.44	-$79.99M	-$0.68	N/A
Theravance Biopharma	$107.46M	8.14	$105.89M	$2.20	7.71

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Beam Therapeutics currently has a consensus price target of $46.83, suggesting a potential upside of 41.06%. Theravance Biopharma has a consensus price target of $21.40, suggesting a potential upside of 26.10%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Beam Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Beam Therapeutics had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Theravance Biopharma. Beam Therapeutics' average media sentiment score of 0.81 beat Theravance Biopharma's score of -0.05 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Theravance Biopharma has a net margin of 104.34% compared to Beam Therapeutics' net margin of -39.66%. Theravance Biopharma's return on equity of 18.84% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Theravance Biopharma	104.34%	18.84%	10.94%

Summary

Beam Therapeutics beats Theravance Biopharma on 10 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Theravance Biopharma had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.05 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Theravance Biopharma has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Theravance Biopharma	$107.46M	8.14	$105.89M	$2.20	7.71

Theravance Biopharma has a net margin of 104.34% compared to Structure Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Theravance Biopharma	104.34%	18.84%	10.94%

Structure Therapeutics has a beta of -1.35, indicating that its stock price is 235% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Structure Therapeutics presently has a consensus target price of $110.55, suggesting a potential upside of 142.37%. Theravance Biopharma has a consensus target price of $21.40, suggesting a potential upside of 26.10%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Structure Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Theravance Biopharma beats Structure Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TBPH vs. The Competition

Export

Metric	Theravance Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$853.72M	$2.96B	$6.44B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	7.71	18.43	24.66	23.99
Price / Sales	8.14	327.41	528.64	107.77
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	2.90	4.11	10.79	6.50
Net Income	$105.89M	$64.45M	$3.56B	$336.88M
7 Day Performance	1.56%	1.41%	1.01%	-0.14%
1 Month Performance	3.67%	1.04%	0.43%	0.77%
1 Year Performance	59.04%	23.88%	29.71%	28.49%

Theravance Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TBPH Theravance Biopharma	2.5174 of 5 stars	$16.97 +2.5%	$21.40 +26.1%	+60.5%	$853.72M	$107.46M	7.71	110
VKTX Viking Therapeutics	2.5438 of 5 stars	$29.18 -1.5%	$93.60 +220.8%	+40.0%	$3.39B	N/A	N/A	20	Options Volume
TLX Telix Pharmaceuticals	4.1529 of 5 stars	$9.62 +0.8%	$21.13 +119.6%	-37.7%	$3.26B	$803.79M	N/A	1,184	Positive News
ARQT Arcutis Biotherapeutics	3.9358 of 5 stars	$25.19 -1.5%	$34.00 +35.0%	+82.4%	$3.15B	$376.07M	N/A	150	Positive News
BEAM Beam Therapeutics	3.276 of 5 stars	$30.40 -2.3%	$46.83 +54.1%	+98.7%	$3.12B	$139.74M	N/A	510

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TBPH) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Theravance Biopharma (TBPH) Competitors

TBPH vs. VKTX, TLX, ARQT, BEAM, and GPCR

How does Theravance Biopharma compare to Viking Therapeutics?

Summary

How does Theravance Biopharma compare to Telix Pharmaceuticals?

Summary

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Theravance Biopharma compare to Beam Therapeutics?

Summary

How does Theravance Biopharma compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Theravance Biopharma (TBPH) Competitors

TBPH vs. VKTX, TLX, ARQT, BEAM, and GPCR

How does Theravance Biopharma compare to Viking Therapeutics?

Does the media refer more to VKTX or TBPH?

Is VKTX or TBPH more profitable?

Do institutionals & insiders hold more shares of VKTX or TBPH?

Do analysts prefer VKTX or TBPH?

Which has preferable valuation and earnings, VKTX or TBPH?

Which has more risk & volatility, VKTX or TBPH?

Summary

How does Theravance Biopharma compare to Telix Pharmaceuticals?

Does the media favor TLX or TBPH?

Is TLX or TBPH more profitable?

Which has better valuation & earnings, TLX or TBPH?

Do analysts recommend TLX or TBPH?

Do institutionals & insiders believe in TLX or TBPH?

Which has more risk and volatility, TLX or TBPH?

Summary

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Do institutionals and insiders have more ownership in TBPH or ARQT?

Which has stronger valuation and earnings, TBPH or ARQT?

Does the media favor TBPH or ARQT?

Which has more volatility and risk, TBPH or ARQT?

Is TBPH or ARQT more profitable?

Do analysts prefer TBPH or ARQT?

Summary

How does Theravance Biopharma compare to Beam Therapeutics?

Which has better earnings & valuation, BEAM or TBPH?

Do insiders and institutionals have more ownership in BEAM or TBPH?

Do analysts prefer BEAM or TBPH?

Does the media favor BEAM or TBPH?

Which has more risk & volatility, BEAM or TBPH?

Is BEAM or TBPH more profitable?

Summary

How does Theravance Biopharma compare to Structure Therapeutics?

Does the media refer more to GPCR or TBPH?

Which has preferable valuation and earnings, GPCR or TBPH?

Is GPCR or TBPH more profitable?

Which has more volatility and risk, GPCR or TBPH?

Do insiders & institutionals hold more shares of GPCR or TBPH?

Do analysts recommend GPCR or TBPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools